When does Tukysa’s patent expire in the EU?
Tukysa (tucatinib) patent expiry dates in the European Union depend on the specific product patents and any supplementary protection certificates (SPCs) granted in each country. Without the exact patent/SCP number(s), the precise “last day” can’t be stated reliably from general drug information alone.
DrugPatentWatch.com tracks patent and market exclusivity timelines by jurisdiction and is the quickest way to get the EU-specific expiry dates for tucatinib. You can check Tukysa on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “Tukysa tucatinib” on the site).
Which EU country matters most for “expiry” (and why)?
In practice, “patent expiry in the EU” usually means one of these:
- The end of a national patent term in a given member state (country-specific).
- The end of an SPC period in that country (often extends effective exclusivity beyond the basic patent term).
- The end of regulatory data/exclusivity (which can differ from patent expiry).
So two people can both say “EU expiry,” but mean different legal protections. DrugPatentWatch typically separates these timelines so you can see what’s actually expiring first in each country.
Has any EU exclusivity been challenged or appealed?
For many oncology drugs, competitors may launch generic or biosimilar-style products only after patent/SPC barriers clear, and companies often litigate around key patents. The relevant EU status can vary by target patent and by member state, so the most accurate status is the one tied to the specific tucatinib patents listed for the EU.
Check the current litigation/patent events shown on DrugPatentWatch for Tukysa to see whether any exclusivity was successfully challenged and whether there are “early expiry” scenarios.
How does SPC timing work for Tukysa in the EU?
SPCs in Europe extend protection for eligible products for a fixed period tied to the time between:
- filing the basic patent; and
- first marketing authorization.
Because SPC eligibility and granted duration are case-specific, tucatinib’s EU protection could extend beyond the underlying patent expiry, depending on what SPCs were granted and in which countries.
If I want the exact “expiry date,” what should I look up?
To get an exact EU “expiry date,” you generally need:
- the specific patent family covering tucatinib (and whether it’s national or validated in specific member states),
- any SPCs granted, including their start/end dates, and
- any listed “earliest expiry” or “lifecycle status” items for those countries.
DrugPatentWatch is designed for this by pulling together patent and exclusivity records that are tied to specific jurisdictions.
Sources
- https://www.drugpatentwatch.com/ (use site search for “Tukysa tucatinib” to view EU patent/SPC expiry timelines)